← Leaderboards
Charles R Rinaldo
University Of Pittsburgh At Pittsburgh
$100,535,685
Attributed
$124,903,288
Total exposure
14
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.2M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$129,657,097 · 16
By mechanism
U01$102,102,652 · 2
R01$14,332,691 · 4
P01$6,292,780 · 3
R37$3,282,700 · 1
U19$1,775,611 · 3
UM1$1,225,641 · 1
Top collaborators
- Jeremy James Martinson18 shared
- Robbie B Mailliard5 shared
- Giovanna Rappocciolo5 shared
- Mackey R Friedman2 shared
- Grace M. Aldrovandi1 shared
- Louis D Falo1 shared
- Andrea Gambotto1 shared
- Mary Elizabeth Hawk1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Candace S Johnson$18,922,226
- Steven A Webber$15,503,800
- Joel L Weissfeld$8,317,064
- Olivera J Finn$21,318,142
- Louis D Falo$30,012,458
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsCohort StudiesCohortParticipantResponseImmuneAcquired Immunodeficiency SyndromeSpecimenVaccinesCd4 Positive T LymphocytesViral Load ResultIncidenceInfectionMen Who Have Sex With MenAnti-Retroviral AgentsDendritic CellsPathogenesisEpidemiologyBiologicalCellsPreventMalignant NeoplasmsCardiovascular SystemLaboratories
Grant awards (105)
University of Pittsburgh MACS/WIHS CCS$3,961,545
U01 · FY2025 · HL · contact PI
Immune response to COVID-19 vaccine in HIV infected men and women$712,337
R01 · FY2025 · AI · contact PI
University of Pittsburgh MACS/WIHS CCS$4,049,466
U01 · FY2024 · HL · contact PI
Immune response to COVID-19 vaccine in HIV infected men and women$739,018
R01 · FY2024 · AI · contact PI
University of Pittsburgh MACS/WIHS CCS$4,084,069
U01 · FY2023 · HL · contact PI
Immune response to COVID-19 vaccine in HIV infected men and women$758,692
R01 · FY2023 · AI · contact PI
University of Pittsburgh MACS/WIHS CCS$4,064,074
U01 · FY2022 · HL · contact PI
Immune response to COVID-19 vaccine in HIV infected men and women$781,490
R01 · FY2022 · AI · contact PI
Association of Oral Microbiome, HIV, and Pulmonary Function$576,878
U01 · FY2022 · HL · contact PI
University of Pittsburgh MACS/WIHS CCS$4,249,415
U01 · FY2021 · HL · contact PI
Immune response to COVID-19 vaccine in HIV infected men and women$788,164
R01 · FY2021 · AI · contact PI
COVID-19 vaccine serologic immune response in people with HIV$751,032
U01 · FY2021 · HL · contact PI
Innovation Fund Application to the MACS/WIHS Combined Cohort Study (MWCCS): COVID-19 Vaccine Acceptance and Hesitancy (CVHB) Study in People with HIV$251,550
U01 · FY2021 · HL · contact PI
University of Pittsburgh MACS/WIHS CCS$4,055,102
U01 · FY2020 · HL · contact PI
Clinical evaluation of SARS-CoV-2 subunit vaccine in a Phase I human clinical study$1,225,641
UM1 · FY2020 · AI
COVID-19 and the MWCCS: Pathophysiology, Impact and Outcomes$359,561
U01 · FY2020 · HL · contact PI
A Training Program to Address HIV-Related Health Disparities in MSM$246,000
T32 · FY2020 · MH · contact PI
MWCCS ETOH supplement$157,146
U01 · FY2020 · HL · contact PI
Study of Hearing and Balance in Middle Aged and Aging Men and Women in the MACS-WIHS Combined Cohort Study$53,185
U01 · FY2020 · HL · contact PI
COVID-19 and the MWCCS: Psychosocial and Structural Impact on Physical and Mental Health, and HIV Prevention Behaviors$22,649
U01 · FY2020 · HL · contact PI
University of Pittsburgh MACS/WIHS CCS$3,600,000
U01 · FY2019 · HL · contact PI
Cholesterol-dependent control of HIV progression by antigen presenting cells$466,486
R01 · FY2019 · AI
University of Pittsburgh MACS/WIHS CCS- Supplement Funds from NHLBI$397,060
U01 · FY2019 · HL · contact PI
A Training Program to Address HIV-Related Health Disparities in MSM$212,464
T32 · FY2019 · MH · contact PI
University of Pittsburgh MACS/WIHS CCS- Supplement Funds from other ICs$53,453
U01 · FY2019 · HL · contact PI
University of Pittsburgh Multicenter AIDS Cohort Study (MACS)$3,752,160
U01 · FY2018 · AI · contact PI
Cholesterol-dependent control of HIV progression by antigen presenting cells$507,143
R01 · FY2018 · AI
A Training Program to Address HIV-Related Health Disparities in MSM$185,800
T32 · FY2018 · MH · contact PI
University of Pittsburgh Multicenter AIDS Cohort Study (MACS)$4,283,706
U01 · FY2017 · AI · contact PI
Cholesterol-dependent control of HIV progression by antigen presenting cells$487,208
R01 · FY2017 · AI
University of Pittsburgh Multicenter AIDS Cohort Study (MACS)$4,773,796
U01 · FY2016 · AI · contact PI
Cholesterol-dependent control of HIV progression by antigen presenting cells$578,731
R01 · FY2016 · AI · contact PI
University of Pittsburgh Multicenter AIDS Cohort Study (MACS)$3,879,805
U01 · FY2015 · AI · contact PI
Cholesterol-dependent control of HIV progression by antigen presenting cells$548,198
R01 · FY2015 · AI · contact PI
University of Pittsburgh Multicenter AIDS Cohort Study (MACS)$3,878,035
U01 · FY2014 · AI · contact PI
Multicenter AIDS Cohort Study$3,731,283
U01 · FY2013 · AI · contact PI
CYTOTOXIC T CELL RESPONSES TO HHV-8$338,781
R01 · FY2013 · CA · contact PI
Anti-HIV T Cell Responses During Antiviral Drug Therapy$314,047
R37 · FY2013 · AI · contact PI
Multicenter AIDS Cohort Study$4,553,096
U01 · FY2012 · AI · contact PI
CYTOTOXIC T CELL RESPONSES TO HHV-8$360,609
R01 · FY2012 · CA · contact PI
Anti-HIV T Cell Responses During Antiviral Drug Therapy$334,092
R37 · FY2012 · AI · contact PI
Multicenter AIDS Cohort Study$3,778,012
U01 · FY2011 · AI · contact PI
CYTOTOXIC T CELL RESPONSES TO HHV-8$360,806
R01 · FY2011 · CA · contact PI
Anti-HIV T Cell Responses During Antiviral Drug Therapy$334,092
R37 · FY2011 · AI · contact PI
Dendritic Cell-Based Immunotherapy for HIV Infection$74,249
U19 · FY2011 · AI · contact PI
Dendritic Cell Core$41,329
U19 · FY2011 · AI · contact PI
Immunotherapy with Autologous HIV-Loaded Dendritic Cells$32,920
U19 · FY2011 · AI · contact PI
Multicenter AIDS Cohort Study$3,677,363
U01 · FY2010 · AI · contact PI
Multicenter AIDS Cohort Study$2,221,266
U01 · FY2010 · AI · contact PI
Multicenter AIDS Cohort Study$415,530
U01 · FY2010 · AI · contact PI
CYTOTOXIC T CELL RESPONSES TO HHV-8$372,163
R01 · FY2010 · CA · contact PI
Anti-HIV T Cell Responses During Antiviral Drug Therapy$337,466
R37 · FY2010 · AI · contact PI
Dendritic Cell-Based Immunotherapy for HIV Infection$75,000
U19 · FY2010 · AI · contact PI
Dendritic Cell Core$41,747
U19 · FY2010 · AI · contact PI
Immunotherapy with Autologous HIV-Loaded Dendritic Cells$33,253
U19 · FY2010 · AI · contact PI
Multicenter AIDS Cohort Study$3,673,937
U01 · FY2009 · AI · contact PI
Multicenter AIDS Cohort Study$1,260,025
U01 · FY2009 · AI · contact PI
Multicenter AIDS Cohort Study$901,232
U01 · FY2009 · AI · contact PI
Multicenter AIDS Cohort Study$591,184
U01 · FY2009 · AI · contact PI
CYTOTOXIC T CELL RESPONSES TO HHV-8$372,355
R01 · FY2009 · CA · contact PI
Anti-HIV T Cell Responses During Antiviral Drug Therapy$340,875
R37 · FY2009 · AI · contact PI
MULTICENTER AIDS COHORT STUDY$3,393,874
U01 · FY2008 · AI · contact PI
Anti-HIV T Cell Responses during Antiviral Drug Therapy$310,793
R37 · FY2008 · AI · contact PI
MULTICENTER AIDS COHORT STUDY$3,560,673
U01 · FY2007 · AI · contact PI
CYTOTOXIC T CELL RESPONSES TO HHV-8$466,150
R01 · FY2007 · CA · contact PI
Anti-HIV T Cell Responses during Antiviral Drug Therapy$316,811
R37 · FY2007 · AI · contact PI
MULTICENTER AIDS COHORT STUDY$3,401,747
U01 · FY2006 · AI · contact PI
Dendritic Cell-Based Immunotherapy for HIV Infection$1,477,113
U19 · FY2006 · AI · contact PI
CYTOTOXIC T CELL RESPONSES TO HHV-8$473,022
R01 · FY2006 · CA · contact PI
Anti-HIV T Cell Responses during Antiviral Drug Therapy$326,274
R37 · FY2006 · AI · contact PI
ANTIGEN DELIVERY FOR ADJUVANT HIV IMMUNOTHERAPY$119,083
P01 · FY2006 · AI · contact PI
CYTOTOXIC T CELL RESPONSES TO HHV-8$100,000
R01 · FY2006 · CA · contact PI
CYTOTOXIC T CELL RESPONSES TO HHV-8$64,917
R01 · FY2006 · CA · contact PI
MULTICENTER AIDS COHORT STUDY$3,466,766
U01 · FY2005 · AI
Dendritic Cell-Based Immunotherapy for HIV Infection$1,500,000
P01 · FY2005 · AI
CYTOTOXIC T CELL RESPONSES TO HHV-8$463,405
R01 · FY2005 · CA
Anti-HIV T Cell Responses during Antiviral Drug Therapy$334,125
R37 · FY2005 · AI
CYTOTOXIC T CELL RESPONSES TO HHV-8$31,418
R01 · FY2005 · CA
CELL MEDIATED IMMUNITY TO HIV, HCV KSHV INFECTIONS$758
M01 · FY2005 · RR
MULTICENTER AIDS COHORT STUDY$2,929,288
U01 · FY2004 · AI
Dendritic Cell-Based Immunotherapy for HIV Infection$874,433
P01 · FY2004 · AI
CYTOTOXIC T CELL RESPONSES TO HHV-8$450,613
R01 · FY2004 · CA
Anti-HIV T Cell Responses during Antiviral Drug Therapy$334,125
R37 · FY2004 · AI
MULTICENTER AIDS COHORT STUDY$2,863,229
U01 · FY2003 · AI
ANTI-HIV T CELL RESPONSES DURING ANTIVIRAL DRUG THERAPY$701,401
R01 · FY2003 · AI
CYTOTOXIC T CELL RESPONSES TO HHV-8$453,729
R01 · FY2003 · CA
Dendritic Cell-Based Immunotherapy for HIV Infection$439,045
P01 · FY2003 · AI
MULTICENTER AIDS COHORT STUDY$2,748,094
U01 · FY2002 · AI
ANTI-HIV T CELL RESPONSES DURING ANTIVIRAL DRUG THERAPY$642,069
R01 · FY2002 · AI
ANTI-HIV T CELL RESPONSES DURING ANTIVIRAL DRUG THERAPY$74,750
R01 · FY2002 · AI
CYTOTOXIC T CELL RESPONSES TO HHV8$74,003
R01 · FY2002 · CA
CYTOTOXIC T LYMPHOCYTE RESPONSES TO SIV INFECTION$0
P01 · FY2002 · AI
ANTIGEN DELIVERY FOR ADJUVANT HIV IMMUNOTHERAPY$1,487,476
P01 · FY2001 · AI
MULTICENTER AIDS COHORT STUDY$1,246,899
U01 · FY2001 · AI
MULTICENTER AIDS COHORT STUDY$1,125,402
U01 · FY2001 · AI
ANTI-HIV T CELL RESPONSES DURING ANTIVIRAL DRUG THERAPY$682,324
R01 · FY2001 · AI
CYTOTOXIC T CELL RESPONSES TO HHV8$357,253
R01 · FY2001 · CA
CYTOTOXIC T CELL RESPONSES TO HHV8$74,200
R01 · FY2001 · CA
CYTOTOXIC T LYMPHOCYTE RESPONSES TO SIV INFECTION$0
P01 · FY2001 · AI
ANTIGEN DELIVERY FOR ADJUVANT HIV IMMUNOTHERAPY$1,520,888
P01 · FY2000 · AI
MULTICENTER AIDS COHORT STUDY$1,310,065
U01 · FY2000 · AI
ANTI-HIV T CELL RESPONSES DURING ANTIVIRAL DRUG THERAPY$682,362
R01 · FY2000 · AI
CYTOTOXIC T LYMPHOCYTE RESPONSES TO SIV INFECTION$351,855
P01 · FY2000 · AI
CYTOTOXIC T CELL RESPONSES TO HHV8$347,470
R01 · FY2000 · CA
CYTOTOXIC T CELL RESPONSES TO HHV8$21,424
R01 · FY2000 · CA